Thymidine Analogue Resistance Suppression By V75i Of Hiv-1 Reverse Transcriptase: Effects Of Substituting Valine 75 On Stavudine Excision And Discrimination. by Matamoros Grande, Tania et al.
 1
THYMIDINE ANALOGUE RESISTANCE SUPPRESSION BY V75I OF HIV-1 
REVERSE TRANSCRIPTASE: EFFECTS OF SUBSTITUTING VALINE 75 ON 
STAVUDINE EXCISION AND DISCRIMINATION*  
 
Tania Matamoros,1 María Nevot,2 Miguel Ángel Martínez2 and Luis Menéndez-Arias1* 
 
1Centro de Biología Molecular “Severo Ochoa”, Consejo Superior de Investigaciones Científicas & 
Universidad Autónoma de Madrid, c/ Nicolás Cabrera 1, Campus de Cantoblanco, 28049 Madrid, Spain; 
2Laboratori de Retrovirologia, Fundació irsiCaixa, Hospital Universitari Germans Trias i Pujol, 
Badalona, 08916 Barcelona, Spain. 
 
Running title:  Thymidine analogue resistance suppression by V75I of HIV-1 RT 
 
Address correspondence to: Luis Menéndez-Arias, Centro de Biología Molecular “Severo 
Ochoa”, c/ Nicolás Cabrera 1, Campus de Cantoblanco, 28049 Madrid, Spain. Tel.: + 34 
911964494; Fax: + 34 911964420; E-mail: lmenendez@cbm.uam.es 
 
 
Val75 of HIV-1 reverse transcriptase (RT) 
plays a role in positioning the template 
nucleotide +1, during the formation of the 
ternary complex.  Mutations such as V75M 
and V75A emerge in patients infected with 
HIV-1 group M-subtype B and group O 
variants, after failing treatment with 
stavudine (d4T) and other nucleoside RT 
inhibitors.  V75I is an accessory mutation 
of the Q151M multi-drug resistance 
complex of HIV-1 RT, and is rarely 
associated with thymidine analogue 
resistance mutations (TAMs).  In vitro, it 
confers resistance to acyclovir.  TAMs 
confer resistance to zidovudine (AZT) and 
d4T by increasing the rate of ATP-
mediated excision of the terminal 
nucleotide monophosphate (primer un-
blocking).  In a wild-type HIV-1 group O 
RT sequence context, V75A and V75M 
conferred increased excision activity on 
d4T-terminated primers, in the presence of 
pyrophosphate (PPi).  In contrast, V75I 
decreased the PPi-mediated unblocking 
efficiency on AZT and d4T-terminated 
primers, in different sequence contexts (i.e. 
wild-type group M-subtype B or group O 
RTs).  Interestingly, in the sequence 
context of an excision-proficient RT (i.e., 
M41L/A62V/T69SSS/K70R/T215Y), the 
introduction of V75I led to a significant 
decrease of its ATP-dependent excision 
activity on AZT-, d4T-, and acyclovir-
terminated primers.  The excision rate of 
d4T-monophosphate in the presence of 
ATP 3.2 mM was about 10 times higher for 
M41L/A62V/T69SSS/K70R/T215Y than for 
the mutant M41L/A62V/T69SSS/K70R/-
V75I/T215Y RT. The antagonistic effect of 
V75I with TAMs was further demonstrated 
in phenotypic assays.  Recombinant HIV-1 
containing the M41L/A62V/T69SSS/-
K70R/V75I/T215Y RT showed 18.3- and 
1.5-fold increased susceptibility to AZT 
and d4T, respectively, in comparison with 
virus containing the M41L/A62V/T69SSS/-
K70R/T215Y RT. 
 
The human immunodeficiency virus type 1 
(HIV-1) reverse transcriptase (RT) plays a 
pivotal role in the viral life cycle and 
therefore, it is an important target for 
antiretroviral drugs such as nucleoside and 
nucleotide RT inhibitors (NRTIs) (1,2).  Once 
phosphorylated by cellular kinases to their 
active triphosphate (TP) forms, NRTIs 
compete with the natural deoxynucleoside 
triphosphates (dNTPs) for incorporation by 
RT into the nascent reverse transcript.  Since 
NRTIs lack a 3´-OH group, their 
incorporation results in chain termination 
(3,4).  The development of resistance remains 
a major problem in the treatment of HIV-1 
infections. HIV-1 becomes resistant to NRTIs 
by (i) improving discrimination against the 
RT inhibitors (5-7), or (ii) by increasing the 
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RT’s ability to remove 3´-terminal chain-
terminator inhibitors from blocked DNA 
primers, through phosphorolysis mediated by 
ATP or pyrophosphate (PPi) (8,9).   
Both resistance mechanisms can be relevant 
in the acquisition of multidrug resistance (for 
recent reviews, see refs. 10,11).  Thus, viral 
RTs bearing mutations A62V, V75I, F77L, 
F116Y and Q151M showed decreased 
discrimination efficiencies against the 
triphosphorylated forms of thymidine 
analogues such as zidovudine (AZT: β-D-(+)-
3´-azido-3´-deoxythymidine) or stavudine 
(d4T: β-D-(+)-2´,3´-didehydro-2´,3´-dideoxy-
thymidine), as well as didanosine, zalcitabine 
and abacavir (6,12,13).  These observations 
were in agreement with the high-level 
resistance to those inhibitors shown in 
phenotypic assays, by HIV variants carrying 
those mutations in their RTs (14,15).  On the 
other hand, resistance to all approved NRTIs 
may be increased by the accumulation of 
thymidine analogue resistance mutations 
(TAMs) (i.e. M41L, D67N, K70R, L210W, 
T215F or Y and K219E or Q) in the absence, 
or in the presence of dipeptide insertions 
between residues 69 and 70. 
Biochemical studies have shown that TAMs 
confer resistance to AZT and other NRTIs by 
accelerating the rate at which the blocking 
AZT monophosphate (MP) (or other 
nucleoside analogue monophosphate) is 
removed through phosphorolytic cleavage.  
RTs containing mutations M41L, A62V, 
T69S, K70R and T215Y, plus a Ser-Ser 
insertion between codons 69 and 70 showed 
very high levels of excision activity with 
primers terminated with AZTMP (16).  
Resistance mechanisms are not mutually 
exclusive. Thus, A62V, an accessory mutation 
of the Q151M complex, was reported to 
increase the ATP-dependent phosphorolytic 
activity on thymidine analogue-terminated 
primers of RTs bearing dipeptide insertions 
(16), while the excision activity promoted by 
the presence of TAMs can be modulated by 
mutations that influence nucleotide 
discrimination (e.g. K65R, L74V, M184V) 
(17-21).   
V75I is an accessory mutation of the Q151M 
multidrug resistance complex of HIV-1 RT 
and contributes to increase zidovudine, 
stavudine, didanosine and zalcitabine 
resistance in the presence of F77L, F116Y 
and Q151M (15,22,23).  In addition, V75I has 
been recently identified as a major acyclovir 
resistance mutation in cells co-infected with 
HIV-1 and herpes simplex virus (24,25).  
Structural analysis of HIV-1 RT showed that 
Val75 plays a role in positioning the template 
nucleotide +1, once the ternary complex is 
formed (26). The side chain of Val75 interacts 
with the side chain of Phe77 to maintain the 
structure of the fingers subdomain. Mutations 
such as V75M, V75T and V75A have been 
reported to occur in about 4% of patients 
infected with HIV-1 group M:subtype B, and 
receiving nucleoside RT inhibitors (NRTIs), 
particularly d4T (http://hivdb.stanford.edu; 
27,28).  In vitro, V75T confers low-level 
resistance to stavudine and other NRTIs (29).  
Mutations at codon 75 have been also 
detected in treated-patients infected with other 
clades of HIV-1. Thus, V75M has been found 
in CRF01_AE-infected patients (30), while 
V75A and V75M have been selected in the 
absence and in the presence of TAMs, 
respectively, in stavudine-treated patients 
infected with HIV-1 group O (31). 
In this study, we have examined the effects on 
stavudine resistance of the amino acid 
substitutions V75A, V75M and V75I in the 
sequence context of a wild-type HIV-1 group 
O RT.  Our data show that V75I reduces 
ATP- and PPi-mediated excision of thymidine 
analogues in different sequence contexts, 
including wild-type variants of group M-
subtype B and group O HIV-1 RTs, as well as 
multidrug-resistant enzymes containing either 
the Q151M complex, or the combination 
M41L/A62V/T69SSS/K70R/T215Y.  These 
results provide evidence of the antagonism 
between V75I and TAMs. 
 
EXPERIMENTAL PROCEDURES 
Reverse transcriptases- Expression and 
purification of BH10_WT RT (wild-type 
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HIV-1BH10 RT), BH10_V75I RT (HIV-1BH10 
RT containing the mutation V75I) and 
Q151Mc RT (HIV-1NL4-3 RT containing 
mutations A62V/V75I/F77L/F116Y/Q151M) 
was performed with modified versions of 
plasmid p66RTB, as previously described 
(12,32-34). For high-level expression of wild-
type HIV-1 group O (O_WT) RT, an insert 
derived from cleavage with EcoRI and XhoI 
of plasmid pRT6, and containing the RT-
coding sequence of the ESP49 variant (35), 
was cloned at the corresponding sites of 
P66RTB(SS) (36). The vector used for high-
level expression of the p66 subunit of the 
MAK_SSSY RT, containing a Ser-Ser 
insertion between codons 69 and 70, and 
mutations M41L, A62V, T69S, K70R and 
T215Y (16), was obtained after cloning the 
SalI-MscI insert purified after cleavage of 
pRT6-derived plasmid, at the appropriate sites 
of p66RTB(Q151Mc) (12). An XhoI site was 
introduced nine nucleotides upstream of the 
sequence encoding for the His6 tag in order to 
eliminate the stop codon generated during the 
cloning process. Site-directed mutagenesis 
was carried out with the QuikChangeTM Site-
Directed Mutagenesis kit (Stratagene) by 
following the manufacturer’s instructions, and 
using the following mutagenic primers: 5’-
GGAATCAGGAAAATACTCGAGTCGAC
TCACCACC-3’ and 5’-GGTGGTGAGTCG-
ACTCGAGTATTTTCCTGATTCC-3’.  The 
introduced mutations were confirmed by 
DNA sequencing. RT p66 subunits carrying a 
His6 tag at their C-terminus were co-
expressed with HIV-1 protease in E. coli XL1 
Blue to obtain p66/p51 heterodimers, which 
were later purified by ionic exchange 
followed by affinity chromatography (32,33). 
RT concentrations were determined by active 
site titration as previously described (37). 
Other mutant RTs were also generated with 
the QuikChangeTM Site-Directed Mutagenesis 
kit, but using plasmids p66RTB(O_WT), 
p66RTB(MAK_SSSY) or p66RTB(Q151Mc) 
as templates. The mutagenic primers used 
were: 5’-AAGTGGAGAAAGCTGGCAGA-
CTTTAGGGAATTAAAC-3’ and 5’-GTT-
TAATTCCCTAAAGTCTGCCAGCTTTCTC
CACTT-3’ for O_V75A; 5’-AAGTGGAG-
AAAGCTGATGGACTTTAGGGAATTAAA
C-3’ and 5’-GTTTAATTCCCTAAAGTCC-
ATCAGCTTTCTCCACTT-3’ for O_V75M; 
5’-AAGTGGAGAAAGCTGATAGACTTT-
AGGGAATTAAAC-3’ and 5’-GTTTAAT-
TCCCTAAAGTCTATCAGCTTTCTCCACT
T-3’ for O_V75I; 5’-GTTCGAGATGG-
AGAAAATTAATAGATTTCAGAGA-3’ 
and 5’-TCTCTGAAATCTATTAATTTTCT-
CCATCTCGAAC-3’ for MAK_SSSY_V75I; 
and 5’-CAGTACTAAATGGAGAAAATTA-
GTAGATCTCAGAGAACTTAATAAGAG-
3’ and 5’-CTCTTATTAAGTTCTCTGAG-
ATCTACTAATTTTCTCCATTTAGTACTG
-3’ for Q151MC_I75V (relevant codons 
underlined). After mutagenesis, the entire RT 
coding regions were sequenced, and if correct, 
used for RT expression and purification. 
Nucleotides and template/primers- Stock 
solutions (100 mM) of dNTPs and ATP were 
obtained from GE Healthcare. AZTTP was 
purchased from Moravek Biochemicals (Brea, 
California). Acyclovir-TP and d4TTP were 
obtained from Sierra Bioresearch (Tucson, 
Arizona). The α-boranophosphate derivative 
of d4TTP (α-BH3-d4TTP) was synthesized as 
previously described (38,39), and its Rp and Sp 
diastereoisomers were purified by reverse-
phase HPLC (40). Before use, nucleoside-TPs 
were treated with inorganic pyrophosphatase 
(Roche) to remove traces of PPi, as described 
(41). DNA oligonucleotides 21P (5’-
ATACTTTAACCATATGTATCC-3’), 
25PGA (5’-TGGTAGGGCTATACATTCTT-
GCAGG-3’), 31T (5’-TTTTTTTTTAGGAT-
ACATATGGTTAAAGTAT-3’), D38 (5’-
GGGTCCTTTCTTACCTGCAAGAATGTA
TAGCCCTACCA-3’), and D38C (5’-
GGGTCCTTTATTCCCTGCAAGAATGTA
TAGCCCTACCA-3’) were obtained from 
Life Technologies. Oligonucleotides 21P and 
25PGA were labeled at their 5’ termini with 
[γ-32P]ATP (Perkin Elmer) and T4 
polynucleotide kinase (Promega), and then 
annealed to their corresponding templates 
(31T and D38, respectively). Template/primer 
31T/21P was used in rapid quench 
incorporation experiments, while D38/25PGA 
was used in chain terminator excision assays, 
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and for the determination of kinetic 
parameters of ATP-dependent phosphorolysis. 
Chain-terminator excision assays- RT-
catalyzed DNA rescue reactions were 
performed with D38/25PGA DNA duplexes, 
as previously described (42,43). Briefly, the 
phosphorylated template/primer (30 nM) was 
preincubated at 37°C for 10 min in the 
presence of the corresponding RT at 12-24 
nM active enzyme concentration, in 50 mM 
Hepes buffer (pH 7.0), containing 15 mM 
NaCl, 15 mM magnesium acetate, 130 mM 
potassium acetate, 1 mM dithiothreitol, and 
5% (w/v) polyethylene glycol 6000. Reactions 
were initiated by adding an equal amount of 
preincubation buffer containing the 
nucleoside RT inhibitor in its tri-
phosphorylated form, at a final concentration 
of 25 µM. After incubating the samples at 
37°C for 30 min, rescue reactions were 
initiated by adding a mixture of all dNTPs at a 
final concentration of 100 µM, in the presence 
of sodium PPi (200 µM) or ATP (3.2 mM) 
depending on the assay. Since the next 
complementary dNTP (dATP, in our assay 
conditions) has an inhibitory effect on the 
rescue reaction, time-courses of the 
unblocking and extension reactions were 
carried out in the presence of 1 µM dATP. In 
experiments designed to assess the inhibitory 
effect of dATP, extension reactions were 
incubated for 5-20 min in the presence of 
different concentrations of dATP. In all of 
those determinations, the amount of rescued 
primer was below 30%. Reactions were 
stopped by adding an equal amount of sample 
loading buffer [10 mM EDTA in 90 % 
formamide containing 3 mg/ml xylene cyanol 
FF and 3 mg/ml bromophenol blue]. Products 
were resolved on a denaturing 20% (w/v) 
polyacrylamide/8 M urea gel, and primer 
rescue was quantified by phosphorimaging 
with a BAS 1500 scanner (Fuji) using the 
program Tina version 2.09 (Raytest 
Isotopenmessgerate Gmbh, Staubenhardt, 
Germany). 
Pre-steady-state kinetics of single nucleotide 
incorporation experiments- Pre-steady-state 
kinetic parameters for the incorporation of 
dTTP and d4TTP by O_WT, O_V75A, 
O_V75M and O_V75I RTs were determined 
with a rapid quench instrument (model QFM-
400, Bio-Logic Science Instruments, Claix, 
France) with reaction times ranging from 10 
ms to 6 s. Reactions were performed under 
single turnover conditions by mixing a 
solution containing 50-100 nM (active sites) 
of HIV-1 RT and 100 nM of the 
template/primer 31T/21P in RT buffer [50 
mM Tris–HCl (pH 8.0), 50 mM KCl], and a 
variable concentration of nucleotide (i.e. 
dTTP or d4TTP) in 12 mM MgCl2, and 
quenched with EDTA (0.3 M final 
concentration). The reaction products were 
separated on a 20% polyacrylamide/urea gel, 
and quantified by phosphorimaging. The 
formation of product [P] over time was fitted 
with the equation: [P]= A x [1-exp (-kobs x t)], 
where A is the amplitude of the burst, and kobs 
is the apparent kinetic constant of formation 
of the phosphodiester bond. Data from single-
turnover experiments were fitted to a single-
exponential equation that measures the rate of 
dNTP incorporation (kobs) per given dNTP 
concentration ([dNTP]). The dependence of 
kobs on [dNTP] is described by the hyperbolic 
equation: kobs = kpol x [dNTP]/(Kd + [dNTP]), 
where Kd and kpol are the equilibrium constant 
and the catalytic rate constant of the dNTP for 
RT, respectively. Kd and kpol were determined 
from curve-fitting using Sigma Plot. 
Pre-steady-state kinetics of the ATP-
dependent excision reaction- For these 
experiments, primer 25PGA was blocked at 
its 3’ end with d4TTP, using terminal 
deoxynucleotidyl transferase as previously 
described (41). Then, the free d4TTP was 
eliminated with a mini Quick SpinTM column 
(Roche). Inhibitor-terminated primer was 
labeled at its 5’ terminus with [γ-32P]ATP and 
T4 polynucleotide kinase, and annealed to 
template D38 as described above. The 38mer 
DNA template primed with 5’-[32P]-labeled 
d4T-terminated 25mer (D38/25PGAd4T) was 
prepared at a final concentration of 1.1 μM. 
Single turnover conditions were used to study 
the excision of d4TMP. A solution containing 
290 nM RT and 45 nM D38/25PGAd4T in RT 
buffer [50 mM Tris–HCl (pH 8.0), 50 mM 
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KCl] was mixed with the same volume of RT 
buffer containing 3.2 mM ATP in the 
presence of 18 mM MgCl2. The reactions 
were carried out for 0 to 30 min at 37°C. 
Aliquots were removed after defined 
incubation periods, quenched with sample 
loading buffer, and analyzed by denaturing 
polyacrylamide gel electrophoresis, as 
described above. The formation of product [P] 
over time was fitted to a single exponential 
decay: [P] = A (exp (-kobs x t). The kobs that 
equals the slope at time zero of the [P] versus 
time plot, was determined from curve fitting 
using Sigma Plot. 
Site-specific footprinting- Site-specific 
footprints with Fe2+ were monitored on 5´ 
end-labeled DNA template. Hybridization of 
the polyacrylamide gel-purified template 
MG48 (5´- GAATCAGCCCTTCCAGTCC-
CCCCTTTTCTTTTAAAAAGTGGCTAAG-
AA-3´) with complementary primer P19 (5´-
TTAAAAGAAAAGGGGGGAC-3´) was 
conducted in a buffer containing 20 mM 
sodium cacodylate (pH 7.0) and 20 mM NaCl, 
by keeping the template/primer at a final 
concentration of 2 μM (44). MG48 is a 5´-end 
truncated version of a previously 
characterized 58-nt template mimicking the 
polypurine tract binding site (45). 
Template/primer (100 nM) was incubated 
with HIV-1 RT (225 nM) in a buffer 
containing 120 mM sodium cacodylate, pH 
7.0, 20 mM NaCl and 0.2 mM MgCl2 a in a 
final volume of 20 μl. Prior to the Fe2+ 
treatment, complexes were preincubated for 
30 min with 25 μM d4TTP or AZTTP (final 
concentration), depending on the assay, and 
then further incubated for 20 min, with 
different concentrations of the next nucleotide 
(dGTP) or phosphonoformic acid, depending 
on the experiments. Treatment with Fe2+ was 
performed essentially as described (44). 
Briefly, pre-formed complexes in a volume of 
20 μl were incubated with a mixture of 2 μl of 
500 μM Fe(NH4)2SO4●6H2O and 2 μl of 500 
μM dithiothreitol. Reactions were allowed to 
proceed for 5 min and then stopped by adding 
100 μl of a solution containing 0.1 M 
thiourea, 2 ng/μl tRNA, 10 mM EDTA and 
0.6 M sodium acetate. Samples were 
subsequently precipitated with ethanol and 
loaded on a 20% denaturing polyacrylamide 
gel, as described above. 
Recombinant virus and drug susceptibility 
tests- These assays were performed as 
described (16,42).  Briefly, full-length RT 
coding sequence DNA was amplified by PCR 
from the different BH10 expression plasmids 
carrying the appropriate RT using the IN5 (5´-
AATTTTCCCATTAGTCCTATTGAAACT
GTACCA-3´) and IN3 (5´-TCTATTCCAT-
CYAAAAATAGTACTTTCCTGATTCC-3´) 
primers. The PCR products were then co-
transfected in MT-4 cells with an RT-deleted 
HXB2-D previously linearized with BstEII 
(46). Culture supernatants were harvested 
when the HIV-1 p24 antigen concentration 
surpassed 20 ng/ml.  Progeny virus was 
propagated and titrated in MT-4 cells. The 
nucleotide sequence of the RT-coding region 
of the progeny virus was PCR amplified with 
the above mentioned primers and checked for 
possible reversions or undesired mutations. 
The MT-4 cells and the deleted HXB2-D 
clone were obtained from the AIDS Reagent 
Program (Medical Research Council). 
Recombinant viruses were tested in triplicate 
with AZT, d4T and ritonavir. The former 
three drugs were obtained from the NIH AIDS 
Research and Reference Reagent Program. 
HIV-1 drug susceptibility data were obtained 
after infecting 30,000 MT-4 cells with 100 
50% tissue culture infective doses of virus, at 
a multiplicity of infection of 0.003, by 
exposing the HIV-1-infected cultures to 
various concentrations of each drug (five-fold 
dilutions).  After the MT-4 cells were allowed 
to proliferate for five days, the number of 
viable cells was quantified by a tetrazolium-
based colorimetric method (MTT method) as 
described elsewhere (47). 
 
RESULTS 
Discrimination between 2´-deoxythymidine 
5´-triphosphate and d4T-triphosphate by 
wild-type and mutant HIV-1 group O RTs – 
Transient kinetic analysis was used to 
investigate the role in stavudine resistance of 
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amino acid substitutions affecting Val75 in 
HIV-1 group O RT.  Mutations V75A and 
V75I had a small effect on the catalytic 
efficiency of dTTP incorporation.  In contrast, 
the relative value of kpol/Kd for d4TTP 
incorporation versus dTTP incorporation was 
significantly reduced for mutant V75I, in 
comparison with the wild-type RT (Table 1).   
These results suggested that V75I could 
confer some resistance, although differences 
with the wild-type enzyme were relatively 
small or non-significant. 
Effects of substituting Val75 in wild-type HIV-
1 RTs on the excision of thymidine analogues 
from blocked DNA primers – The ability of 
RTs to unblock d4TMP-terminated primers 
was assessed by using the template/primer 
shown in Fig. 1A.  These experiments were 
carried out in two steps.  First, the enzyme 
and the template/primer were incubated in the 
presence of d4TTP to generate a terminated 
26-nucleotide primer.  Then, unblocking and 
extension reactions were carried out by 
adding a mixture of dNTPs and PPi (200 μM) 
or ATP (3.2 mM).   These assays revealed that 
in comparison with the wild-type HIV-1 
group O RT, mutants V75A and V75M had 
increased excision activity on d4TMP-
terminated primers, thereby promoting 
stavudine resistance (Fig. 1B).  Interestingly, 
the mutation V75I produced a significant 
decrease in the PPi-mediated excision 
activity.  This effect was also observed when 
the V75I mutation was introduced in the HIV-
1 group M:subtype B sequence context (i.e. in 
the RT of the BH10 strain), but the 
differences between mutants V75A, V75M 
and the wild-type enzyme were not significant 
(Fig. 1C).  The reduced phosphorolytic 
activity of RTs bearing the V75I mutation was 
also observed in ATP-mediated excision 
assays, although the efficiency of the 
unblocking reaction was relatively low.  After 
incubating for 30 min in the presence of 3.2 
mM ATP, in the conditions described in the 
legend to Fig. 1, O_WT, O_V75I, BH10_WT 
and BH10_V75I RTs were able to unblock 
and extend 9.5, 6.0, 12.2 and 8.0% of the 
d4TMP-terminated primer, respectively. The 
diminished excision activity associated with 
the V75I mutation was also observed with 
primers blocked with AZTMP, and was 
independent of the RT sequence context, as 
shown in Fig. 1D. 
Effects of V75I on the excision activity of 
multidrug-resistant RTs – The effects of 
substituting Ile for Val75 were also analyzed 
in the sequence context of multidrug resistant 
RTs, such as the one containing the Q151M 
mutation complex (Q151Mc RT) or an 
excision-proficient RT carrying a Ser-Ser 
insertion between codons 69 and 70, and 
mutations M41L, A62V, T69S, K70R and 
T215Y (MAK_SSSY RT).  As shown in Fig. 
2, a reduction in the ATP- or PPi-mediated 
excision activity on primers terminated with 
d4TMP was obtained by introducing the V75I 
mutation in the MAK_SSSY RT.  In addition, 
eliminating the V75I mutation from the 
Q151Mc RT sequence rendered an enzyme 
with slightly increased excision activity.  The 
largest effects of substituting Val or Ile at 
position 75 were observed with the 
MAK_SSSY RT mutant in ATP-dependent 
phosphorolytic reactions.   
The d4TMP excision rates for MAK_SSSY 
RT and its derivative containing V75I were 
determined in the presence of 3.2 mM ATP, 
under single-turnover conditions and using a 
d4TMP-terminated primer which was 
previously annealed to a 38-nucleotide 
template (D38) (Fig. 3).    MAK_SSSY RT 
showed an excision rate (kobs) of 0.178 ± 
0.007 min-1, and the introduction of V75I in 
the sequence context of MAK_SSSY RT led 
to a 10-fold decrease of the excision rate (kobs 
value was 0.0167 ± 0.0014 min-1). 
Excision reactions can be inhibited by the 
next complementary nucleotide.  We and 
others have shown that the ATP-mediated 
excision of d4TMP from blocked primers can 
be inhibited in vitro at concentrations of the 
next complementary dNTP between 0.5 and 
25 μM (41,48).  In the presence of 3.2 mM 
ATP, the MAK_SSSY RT showed an IC50 for 
the next complementary dNTP of 6.37 ± 0.62 
μM, while its mutant derivative carrying the 
V75I mutation was about three times less 
susceptible to dNTP inhibition (IC50 = 17.73 ± 
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4.01 μM).  These results suggested that the 
V75I mutation could interfere with the 
excision activity by affecting the translocation 
state of the blocked template/primer. 
Site-specific footprinting experiments using 
the classical method with [Fe(EDTA)]2– that 
yields hydroxyl radicals via Fenton-like 
chemistry (44) were carried out in order to 
determine the impact of V75I on the 
translocation status of HIV-1 RT.  DNA/DNA 
duplexes containing the MG48 template and 
the primer P19 terminated with d4TTP or with 
AZTTP were used as substrates (Fig. 4).   In 
the presence of MG48/P19, treatment with 
Fe2+ caused site-specific cleavage at positions 
−17 and −18, which correspond to post-
translocational (P-site complex) and pre-
translocational (N-site complex) 
configurations of the template/primer in the 
HIV-1 RT. Fe2+-mediated cuts were assigned 
by means of a T-ladder (Fig. 4B).  
As expected, the addition of the next 
complementary dNTP (i.e. dGTP under our 
assay conditions) promoted the formation of 
the ‘dead-end’ complex and the inhibition of 
the excision reaction, while leading to a 
significant increase of the intensity of the 
band at position -17, corresponding to the 
post-translocational configuration of the viral 
RT (Fig. 4B). On the other hand, foscarnet 
shifts the translocational equilibrium towards 
a pre-translocated (and sometimes, 
hypertranslocated) position (50,51) (Fig. 4B).    
Fig. 4C shows the distribution of pre- and 
post-translocated complexes in the presence 
of increasing concentrations of dGTP for the 
multidrug-resistant mutant 
M41L/A62V/T69SSS/K70R/T215Y and its 
derivative containing V75I. The dGTP 
concentration required to obtain 50% of 
complexes in the post-translocational stage 
was >1000 times lower for dd4TMP- than for 
AZTMP-terminated primers.  Differences 
between M41L/A62V/T69SSS/K70R/T215Y 
and M41L/A62V/T69SSS/K70R/V75I/T215Y 
were non-significant for AZTMP-terminated 
primers.  However, in the presence of 
d4TMP-terminated primers, the MAK_SSSY 
RT showed a higher preference for the post-
translocational configuration.  Estimates of 
the concentrations of dGTP required to obtain 
50% of the complexes in the post-
translocational stage were 0.29 ± 0.06 μM for 
MAK_SSSY RT, and 0.62 ± 0.15 for 
MAK_SSSY_V75I RT.  
Other RTs (i.e. wild-type BH10 RT, wild-type 
group O RT, and the multidrug-resistant 
mutant A62V/F77L/F116Y/Q151M, as well 
as their derivatives with V75I) showed similar 
cleavage patterns, with small differences in 
the band intensities at positions -17 and -18 
(Fig. 5).  However, higher dGTP 
concentrations were required to shift the 
equilibrium towards the post-translocational 
stage for O_WT and O_V75I RTs than for the 
other enzymes. Interestingly, in comparison 
with the mutant BH10_V75I, the BH10_WT 
RT showed a higher preference for the post-
translocational stage within the range of 0.05-
0.5 μM dGTP.  However the effects of V75I 
on the translocational equilibrium of O_WT 
and A62V/V75I/F77L/F116Y/Q151M RTs 
were not significant.   
These results were also broadly in agreement 
with site-specific footprinting experiments 
carried out with the template-primer used in 
the dNTP inhibition experiments (i.e. 
D38/25PGA), that showed that V75I had an 
impact on the formation of the ‘dead-end’ 
complex both in the presence of wild-type 
BH10 RT or in the presence of the mutant 
M41L/A62V/T69SSS/K70R/T215Y (data not 
shown). 
Further excision experiments with d4TMP-
terminated primers showed that the V75I 
mutation impaired both the ATP- and the PPi-
dependent phosphorolytic activity of the 
multidrug-resistant RT containing the 
insertion and the accompanying TAMs (i.e. 
M41L/A62V/T69SSS/K70R/T215Y), in 
reactions carried out with DNA duplexes 
containing an AZTMP-terminated primer 
(Fig. 6A).  The peptide backbone of Val75 
interacts with the 5´ template overhang in the 
ternary complex of HIV-1 RT, although an 
indirect effect on Gln151 and other residues in 
the dNTP binding site could also occur and 
affect the enzyme’s activity (26,34). The 
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geometry of the phosphodiester bond at the 3´ 
end of the primer could interfere with 
excision.  However, the time courses of the 
excision reactions carried out with primers 
terminated with the Rp and Sp 
diastereoisomers of α-borano derivatives of 
d4TMP [i.e. α-(Rp)-BH3-d4TMP and α-(Sp)-
BH3-d4TMP] were almost identical (Fig. 6B).  
However, in all cases, the V75I mutation 
produced a significant decrease in the 
excision rate, which was larger in ATP-
dependent phosphorolytic reactions. 
Interestingly, V75I also impaired the excision 
activity on primers terminated with acyclovir 
(Fig. 6C), suggesting a broad impact on ATP-
dependent phosphorolytic activity on primers 
blocked with several chain-terminating 
inhibitors.  However, it should be noted that 
V75I impairs the incorporation of acyclovir-
TP (25) and therefore, acyclovir excision is 
not expected to be relevant in vivo. 
Phenotypic drug susceptibility of recombinant 
HIV-1 – Recombinant HIV-1 clones contain-
ing the excision-proficient MAK_SSSY RT 
and its derivative containing V75I (i.e. 
M41L/A62V/T69SSS/K70R/V75I/T215Y) 
were assayed to establish the level of 
resistance to thymidine analogues.  As 
reported in Table 2, the MAK_SSSY RT 
conferred >80-fold increased AZT resistance 
and 5.8-fold increased d4T resistance in 
comparison with wild-type HIV-1 containing 
the BH10 RT.  The V75I mutation decreased 
resistance to both thymidine analogues, 
although the effects were much more 
significant with AZT.   
 
DISCUSSION 
Despite the significant advances in 
antiretroviral therapy, and the increasing 
knowledge about drug resistance mutations, 
interpretation of mutational patterns is often 
difficult due to poor phenotypic correlates, 
unexpected interactions between amino acid 
substitutions involved in resistance and 
uncertainties on the contribution of secondary 
mutations in different sequence contexts. 
Several mutations at codon 75, such as V75A, 
V75T or V75M have been related to stavudine 
resistance in major clades of HIV-1 (e.g. 
group M:subtype B and group O strains) 
(27,29-31,52).  Our kinetic analysis of 
nucleotide incorporation shows that in the 
sequence context of an HIV-1 group O RT, 
V75M has only slightly increased 
discrimination ability between d4TTP and 
dTTP in comparison with the wild-type 
enzyme.  However, both stavudine-related 
mutations V75M and V75A were shown to 
confer increased phosphorolytic activity on 
d4TMP-terminated primers (Fig. 1), a result 
which is consistent with their selection in vivo 
in stavudine-treated patients which were 
infected with HIV-1 group O variants (31).   
However, these differences were not observed 
with a prototypic HIV-1 group M:subtype B 
RT (i.e. BH10 RT).   
Interestingly, our analysis shows that V75I 
has a minor influence on discrimination 
between d4TTP and dTTP, but impairs 
thymidine analogue excision in different RT 
sequence contexts, including wild-type and 
drug-resistant enzymes (Figs. 1 and 2).  
Reversion of the excision phenotype by V75I 
was particularly evident with the mutant 
containing the dipeptide insertion and TAMs 
such as M41L, K70R and T215Y. 
Val75 is located in the β3-β4 hairpin loop 
(residues 56-77) and plays a role in 
positioning the template nucleotide +1 during 
the formation of the ternary complex of RT, 
duplex DNA and the incoming dNTP (26). 
The comparison with the crystal structure of 
the HIV-1 RT binary complex (53) revealed 
that in the ternary complex, the distances 
between the peptide backbones of Val75 and 
Gln151 and between Val75 and the  single-
stranded template were reduced (34). In 
addition, the side chain of Val75 interacts 
with residues such as Val60, Phe77 or Tyr146 
that are important to maintain the structure of 
the fingers subdomain while influencing the 
architecture of the dNTP binding site (52).  It 
has been shown that in a subtype B HIV-1 RT 
sequence context, V75T increases d4T 
excision (52), while V75I has the opposite 
effect (this work). Subtle differences affecting 
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the accessibility of the PPi donor to the 
terminating nucleotide at the 3´ end of the 
primer could be invoked to explain the 
observed differences, although further studies 
will be necessary to provide a reliable 
mechanistic interpretation. 
In agreement with the results obtained with 
purified RTs, phenotypic assays revealed that 
the recombinant HIV-1 containing mutations 
M41L/A62V/T69SSS/K70R/V75I/T215Y 
was about 18 times more susceptible to AZT 
than its homologous lacking the V75I change.  
These results were also consistent with the 
predicted AZT fold-change values of 3.3 and 
22.3, obtained for M41L/A62V/T69SSS/-
K70R/V75I/T215Y and M41L/A62V/-
T69SSS/K70R/T215Y respectively, using the 
VirtualPhenotypeTM-LM bio-informatics tool 
(Virco BVBA, Mechelen, Belgium).  
However, as anticipated by the 
VirtualPhenotypeTM-LM predictions, V75I 
had a relatively small impact on d4T 
resistance in phenotypic assays, as a 
consequence of the inhibition of the excision 
reaction by the relatively high dNTP levels 
found in the MT-4 cells used in the drug 
susceptibility assays.  Phenotypic assays with 
recombinant HIV-1 clones also showed that 
the addition of V75I to an RT sequence 
background containing M41L, A62V, T69S, 
K70R, V75I, T215Y, and the Ser-Ser 
insertion between positions 69 and 70 had an 
antagonistic effect on d4T resistance.   
Our results demonstrate that V75I shares a 
common biochemical mechanism with RT 
mutations such as K65R (21,54), L74V 
(19,20), Y181C (55), M184V (17,18), as well 
as with a number of foscarnet-related 
resistance mutations (i.e. W88G, E89K, 
A114S, S117T, Q161L and M164I) (56,57) 
and with the deletion of Thr69, which is often 
associated with the Q151M complex (58-60).  
All of those mutations increase HIV-1 
susceptibility to AZT by reducing the 
phosphorolytic activity of the enzyme.  
Phenotypic drug susceptibility assays have 
demonstrated that as in the case of V75I, other 
amino acid changes (e.g. K65R, L74V, 
W88G, E89K, L92I, A114S, S117T, S156A, 
F160Y, Q161L, M164I, Y181C, M184V) are 
able to enhance AZT susceptibility in the 
presence of TAMs (17,20,21,55-57,61,62).   
V75I impairs excision by reducing the rate of 
chain-terminator removal. Moreover, in the 
presence of TAMs, V75I contributes to 
increase the IC50 for the next complementary 
nucleotide, by facilitating the pre-
translocation configuration of the d4TMP-
terminated primer.  However, the effects of 
V75I on the formation of a dead-end complex 
with primers terminated with d4T could be of 
little significance due to the relatively small 
differences between the IC50 values obtained 
with excision-proficient RTs with or without 
V75I.  On the other hand, as in the case of 
L74V or M184V (19), V75I does not affect 
the translocational equilibrium in the presence 
of the next complementary dNTP when the 
primer is blocked with AZTMP.  
The relevance of the ATP-dependent 
phosphorolytic mechanism in vivo depends on 
the concentration of ATP, and the dNTP 
levels inside the cell. Estimates of dNTP 
concentrations ranged from 0.2 μM to 24.5 
μM in resting human lymphocytes, while 
concentrations can be 2- to 10-fold higher in 
activated human lymphocytes, depending on 
the assay conditions and dNTP analysed. The 
highest dNTP levels have been reported for 
established cell lines, such as H-9, U937 
promonocytes, CEM lymphoblasts or SupT1 
cells, where nucleotide concentrations range 
from 50 μM to 300 μM (for reviews, see refs. 
63,64).  Under these conditions, it is clear that 
rescue of inhibitor-terminated primers could 
be more relevant for the acquisition of 
resistance to AZT than for d4T (41, 48).  
 
Despite the extensively reported evidence of 
cross-resistance between AZT and d4T in 
clinical settings (65-67), the relatively high 
dNTP levels could explain the large 
differences between AZT and d4T 
susceptibilities obtained in phenotypic assays 
(65,68,69). For example, 
M41L/L210W/T215Y confers >100-fold 
increased resistance to AZT in phenotypic 
assays, but only a 2.1-fold increase in the IC50 
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for d4T relative to the wild-type HIV-1 (70). 
In contrast, in the presence of M184V, 
M41L/L210W/T215Y conferred 15-fold 
increased resistance to AZT, but a mere 1.8-
fold increased resistance to d4T.  It is widely 
accepted that M184V impairs excision of 
thymidine analogues (17,18), but in 
phenotypic assays these effects which are 
clearly detectable with AZT, are only 
marginal with d4T, due to the high dNTP 
levels present in SupT1 and MT-4 cells.   In 
this context, our phenotypic data showing a 2-
fold reduction of the IC50 for d4T when V75I 
is present are most significant. The 
biochemical studies reported in this work also 
suggest that this reduction is a consequence of 
the lower d4TMP excision rate of the V75I-
containing RT, rather than an effect of its 
decreased susceptibility to dNTP inhibition. 
 
An extensive analysis of amino acid 
covariation in RT sequences from more than 
7,000 people infected with HIV-1 group 
M:subtype B virus obtained from the Stanford 
HIV Drug Resistance Database has revealed 
that V75I is strongly associated with 
mutations of the Q151M complex, whereas 
V75M is positively associated with TAMs 
such as M41L, L210W or T215Y (71).  The 
antagonistic effects between V75I and TAMs 
could be relevant for the acquisition of AZT 
resistance in HIV-2.  Wild-type HIV-2 RT 
contains Ser instead of Thr at position 215 
and only one nucleotide change is needed to 
obtain the substitution S215Y.  However, 
Q151M emerges as the major AZT resistance 
mutation in HIV-2 RT, whereas TAMs are 
relatively uncommon in HIV-2-infected 
patients (72-74). Molecular modelling studies 
suggested that several amino acid differences 
around the putative ATP binding site of HIV-
2 RT in comparison with the HIV-1 RT could 
account for these differences (75).  The 
presence of Ile75 in the wild-type HIV-2 RT 
and our results showing the diminished 
excision activity conferred by V75I provide 
additional arguments to explain why the 
Q151M pathway is preferred over the 
accumulation of TAMs in the acquisition of 
thymidine analogue resistance in HIV-2.   
     
Finally, it should be noted that our study also 
reveals that accessory mutations in the 
Q151M complex could have different effects 
on excision, since we have previously 
demonstrated that A62V contributes to 
increase ATP-mediated excision of thymidine 
analogues in the presence of one, two or three 
TAMs (16).  From a mechanistic point of 
view, antagonistic mutations are likely to 
affect the optimal alignment of the PPi donor 
with the phosphodiester group located at the 
3´ end of the blocked primer.  A more 
complete understanding of the precise 
mechanisms underlying these interactions 
may come from the determination of the 
crystal structures of ternary complexes 
containing RTs carrying the relevant 
combinations of mutations. 
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FOOTNOTES 
HIV-1, human immunodeficiency virus type 1; RT, reverse transcriptase; NRTIs, nucleoside 
RT inhibitors; TP, triphosphate; dNTPs, deoxynucleoside triphosphates; AZT, 3´-azido-3´-
deoxythymidine; d4T, 2´,3´-didehydro-2´,3´-dideoxythymidine; TAM, thymidine analogue 
resistance mutation; MP, monophosphate; WT, wild-type; α-BH3, α-borano;  
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LEGENDS TO FIGURES 
 
FIGURE. 1. Effect of amino acid substitutions affecting Val75 in phylogenetically diverse 
HIV-1 RTs, on rescue DNA polymerization reactions carried out in the presence of PPi. (A) 
Reactions were carried out with 38/25mer DNA/DNA heteropolymeric complexes (sequences 
shown above). First, the inhibitor was incorporated at position +1 of the 25 nt-primer (lane P), 
to generate a 26 nt-product (lane B). Excision of d4TMP and further primer extension in the 
presence of 3.2 mM ATP or 200 µM PPi ,and a mixture of dNTPs leads to the formation of a 
fully extended 38 nt-product. The next complementary dNTP (dATP, in the assay conditions) 
can inhibit the rescue reaction. Time-courses of primer rescue reactions are shown in lanes 1-9 
which correspond to aliquots removed 1, 2, 3, 4, 5, 6, 8 and 10 min after addition of 200 µM 
PPi. The time-courses of primer rescue reactions initiated from d4T-terminated primers using 
wild-type and mutant HIV-1 group O RTs, and wild-type and mutant HIV-1 group M:subtype 
B RTs are shown in panels (B) and (C), respectively.  (D) Effect of V75I on rescue reactions 
initiated from AZT-terminated primers. All dNTPs in the assays were supplied at 100 µM, 
except for dATP whose concentration was 1 µM. Active enzyme concentration in these assays 
was 12 nM. Represented values were obtained from two to three independent experiments.  
 
 
FIGURE 2. Effect of substituting Val for Ile75 or Ile for Val75 in multidrug-resistant RTs, on 
rescue DNA polymerization reactions initiated from d4T-terminated primers. Time-courses of 
excision reactions were carried out in the presence of 3.2 mM ATP (left panel) or 200 µM PPi 
(right panel). Assays were done with the template/primer shown in Fig. 1A. All dNTPs in the 
assays were supplied at 100 µM, except for dATP whose concentration was 1 µM. Active 
enzyme concentration in these assays was 12 nM. Represented values were obtained from two 
to three independent experiments. Interassay variability was below 12% in these experiments. 
 
 
FIGURE 3. Effects of V75I on the kinetics of ATP-dependent excision activity of MAK_SSSY 
RT. Time-courses for the excision reaction of a d4T-terminated primer (26mer) annealed to a 
38mer DNA template (45 nM), catalyzed by MAK_SSSY and MAK_SSSY_V75I RTs (290 
nM) were determined in the presence of 3.2 mM ATP. Lane P shows the d4T-terminated primer 
before treatment with ATP. The time courses of the reactions are shown in lanes 1 to 12, where 
samples correspond to aliquots removed 15, 30, 60, 120, 240, 360, 480, 600, 720, 900, 1200 
and 1800 s after the addition of ATP.  
 
 
FIGURE 4. Site-specific footprinting of RT-DNA/DNA complexes. (A) Sequence of the 
DNA/DNA template/primer indicating the hyperreactive cleavage sites (at positions -16, -17 
and -18). The 32P-labelled 5´ end of the template is marked with an asterisk. (B) Cleavage 
patterns obtained after treatment with Fe2+, using MAK_SSSY RT and the DNA duplex 
containing a d4TMP-terminated primer in the absence and in the presence of the next 
complementary dNTP (i.e. dGTP). Lane T shows a T-ladder obtained with KMnO4-piridine 
(49).  (C) Cleavage patterns obtained after Fe2+ treatment of RT-DNA/DNA complexes in the 
absence of nucleotide (lane 0) or in the presence of different concentrations of dGTP: 0.01 μM 
(lane 1), 0.05 μM (lane 2), 0.1 μM (lane 3), 0.2 μM (lane 4), 0.5 μM (lane 5), 1 μM (lane 6), 
3.125 μM (lane 7), 6.25 μM (lane 8), 12.5 μM (lane 9), 25 μM (lane 10), 50 μM (lane 11), 100 
μM (lane 12), 250 μM (lane 13), 500 μM (lane 14), 1 mM (lane 15) and 5 mM (lane 16), or in 
the presence of 500 μM foscarnet (lane F). C, stands for a control carried out in the absence of 
 15
Fe2+. The graphs below show the nucleotide-dependent changes of the translocation status with 
MAK_SSSY and MAK_SSSY_V75I RTs, in the presence of d4TMP-terminated primers (left) 
or AZTMP-terminated primers (right). 
 
 
FIGURE 5. Site-specific footprinting of RT-DNA/DNA complexes containing d4TMP-
terminated primers. Cleavage patterns obtained after Fe2+ treatment of RT-DNA/DNA 
complexes in the absence of nucleotide (lane 0) or in the presence of different concentrations of 
dGTP: 0.01 μM (lane 1), 0.05 μM (lane 2), 0.1 μM (lane 3), 0.2 μM (lane 4), 0.5 μM (lane 5), 1 
μM (lane 6), 6.25 μM (lane 7), 25 μM (lane 8), 100 μM (lane 9) and 500 μM (lane 10), or in the 
presence of 500 μM foscarnet (lane F). C, stands for a control carried out in the absence of Fe2+. 
The graphs below show the nucleotide-dependent changes of the translocation status with 
BH10_WT and BH10_V75I RTs (left), O_WT and O_V75I RTs (center) and Q151Mc and 
Q151Mc_I75V RTs (right). Estimates of the dGTP concentrations required to obtain 50% of the 
complexes in the post-translocational stage were 0.079 ± 0.012 μM for BH10_WT RT, 0.22 ± 
0.04 μM for BH10_V75I, 0.50 ± 0.15 μM for O_WT RT, 0.45 ± 0.21 for O_V75I RT, 0.098 ± 
0.027 μM for Q151Mc RT, and  0.112 ± 0.029 μM for Q151Mc_I75V RT. 
 
 
FIGURE 6. Effects of V75I on rescue DNA polymerization reactions initiated from primers 
terminated with AZTMP (A), α-BH3-d4TMP diastereoisomers (B) or acyclovir-MP (C). Panels 
shown on the left correspond to reactions carried out in the presence of 3.2 mM ATP, while 
those on the right were obtained with 200 μM PPi. The assays in panels (A) and (B) were 
performed with the template/primer shown in Fig. 1A, while the template/primer D38C/25PGA 
was used in rescue reactions carried out with primers terminated with acyclovir-MP. All dNTPs 
were supplied at 100 µM, except for dATP whose concentration was 1 µM. Active RT 
concentration in these assays was 12 nM. Represented values were obtained from two to three 
independent experiments. Interassay variability was below 12% in these experiments. 
 
